The main purposes of this study are to evaluate the safety and how well the body handles
single and multiple doses of increasing strength of study drug, LY3127760. This study
includes three parts. Part 3 may be initiated at sponsor's discretion, based on data from
Part 2. Participants will only enroll in 1 of the 3 study parts. This study will last
approximately 7 to 13 weeks, depending on part. Screening must be completed within 28 days
prior to enrollment.